Cargando…

Clinically relevant inflammatory breast cancer patient-derived xenograft–derived ex vivo model for evaluation of tumor-specific therapies

Inflammatory breast cancer (IBC) is a rare and aggressive presentation of invasive breast cancer with a 62% to 68% 5-year survival rate. It is the most lethal form of breast cancer, and early recognition and treatment is important for patient survival. Like non-inflammatory breast cancer, IBC compri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eckhardt, Bedrich L., Gagliardi, Maria, Iles, LaKesla, Evans, Kurt, Ivan, Cristina, Liu, Xiuping, Liu, Chang-Gong, Souza, Glauco, Rao, Arvind, Meric-Bernstam, Funda, Ueno, Naoto T., Bartholomeusz, Geoffrey A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955489/ https://www.ncbi.nlm.nih.gov/pubmed/29768500 http://dx.doi.org/10.1371/journal.pone.0195932

Ejemplares similares

Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
por: Le Du, Fanny, et al.
Publicado: (2015)

Genome-wide siRNA screen identifies UNC50 as a regulator of Shiga toxin 2 trafficking
por: Selyunin, Andrey S., et al.
Publicado: (2017)

CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts
por: Huang, Licai, et al.
Publicado: (2022)

A target of potential RELAvance in inflammatory breast cancer
por: Eckhardt, Bedrich L., et al.
Publicado: (2017)

Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
por: Yi, Xue, et al.
Publicado: (2022)

Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat
por: Cheng, Tiewei, et al.
Publicado: (2021)

Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression
por: Park, Jihyun, et al.
Publicado: (2021)

Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes
por: McAuliffe, Priscilla F., et al.
Publicado: (2015)

Challenges and perspective of drug repurposing strategies in early phase clinical trials
por: Kato, Shumei, et al.
Publicado: (2015)

Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes
por: McAuliffe, Priscilla F., et al.
Publicado: (2016)

Whole Genome Sequencing in Cancer Clinics
por: Chen, Ken, et al.
Publicado: (2014)

Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer
por: Lee, Jangsoon, et al.
Publicado: (2015)

Personalized cancer therapy—leveraging a knowledge base for clinical decision-making
por: Dumbrava, Ecaterina Ileana, et al.
Publicado: (2018)

Targeting translation initiation in breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2014)

PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery
por: Koc, Soner, et al.
Publicado: (2022)

Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis
por: Kono, Miho, et al.
Publicado: (2018)

The rapamycin-regulated gene expression signature determines prognosis for breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2009)

Optimizing Drug Response Study Design in Patient-Derived Tumor Xenografts
por: Weiss, Jessica, et al.
Publicado: (2022)

Patient-derived xenograft models of breast cancer and their predictive power
por: Whittle, James R, et al.
Publicado: (2015)

Patient-derived xenografts: a relevant preclinical model for drug development
por: Pompili, Luca, et al.
Publicado: (2016)

Clinically relevant orthotopic xenograft models of patient-derived glioblastoma in zebrafish
por: Ai, Xiaolin, et al.
Publicado: (2022)

Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment
por: Sun, Hua, et al.
Publicado: (2021)

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer
por: Arango, Natalia Paez, et al.
Publicado: (2017)

Patient Derived Xenografts Expand Human Primary Pancreatic Tumor Tissue Availability for ex vivo Irreversible Electroporation Testing
por: Brock, Rebecca M., et al.
Publicado: (2020)

Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells
por: Sugimoto, Takeshi, et al.
Publicado: (2007)

The Application of Patient-Derived Xenograft Models in Gynecologic Cancers
por: Jiang, Wenxiao, et al.
Publicado: (2020)

EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer
por: Wang, Xiaoping, et al.
Publicado: (2017)

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts
por: Woo, Xing Yi, et al.
Publicado: (2021)

Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel
por: Shen, Chan, et al.
Publicado: (2016)

Hypoxia-regulated gene expression explains differences between melanoma cell line-derived xenografts and patient-derived xenografts
por: Bhadury, Joydeep, et al.
Publicado: (2016)

Efficacy of Quality Criteria to Identify Potentially Harmful Information: A Cross-sectional Survey of Complementary and Alternative Medicine Web Sites
por: Walji, Muhammad, et al.
Publicado: (2004)

CK1α-targeting inhibits primary and metastatic colorectal cancer in vitro, ex vivo, in cell-line-derived and patient-derived tumor xenograft mice models
por: Ren, Fupeng, et al.
Publicado: (2020)

Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment
por: Sun, Hua, et al.
Publicado: (2022)

Patient-derived xenografts as preclinical neuroblastoma models
por: Braekeveldt, Noémie, et al.
Publicado: (2017)

Patient-derived xenograft models in musculoskeletal malignancies
por: Lu, Wan, et al.
Publicado: (2018)

Patient-Derived Xenograft Models in Cancer Research
por: van Weerden, Wytske M.
Publicado: (2021)

Patient-derived xenograft models in hepatopancreatobiliary cancer
por: Pan, Binhua, et al.
Publicado: (2022)

A Patient-Derived Xenograft Model of Glioblastoma
por: Chokshi, Chirayu R., et al.
Publicado: (2020)

FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2019)

Correction: FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_msaasf4bjq42sh6qq6rs45rh88